Shortening the Oral Sodium Loading Test for Diagnosing Primary Aldosteronism
Official title: Consistency of 24-hour Urinary Aldosterone on on the Second Day and the Third Day in Diagnosis of Primary Aldosteronism Measured in the Oral Sodium Loading Test by Liquid Chromatography-tandem Mass Spectrometry
Run by Peking Union Medical College Hospital · NCT06750172 · Data updated 2026-11-12
This study is testing if a shorter 2-day sodium loading test can accurately diagnose primary aldosteronism, compared to the traditional 3-day method, for people with this condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | December 15, 2023 |
| Main results expected | December 25, 2024 |
| Study ends | December 25, 2024 |
| Registry record updated | December 27, 2024 |
| Trial ID | NCT06750172 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 20-70 with hypertension and hypokalemia diagnosed with primary aldosteronism.
✕Probably not a fit
Patients with other causes of endocrine hypertension or significant comorbid conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to compare the effectiveness of a 2-day oral sodium loading test against the traditional 3-day method for diagnosing primary aldosteronism. It involves 17 healthy controls and 15 patients diagnosed with primary aldosteronism, who will follow a high-sodium diet for 3 days. The study will measure 24-hour urinary aldosterone levels on both the second and third days to determine if the shorter test can reliably replace the longer one. The goal is to simplify the diagnostic process while maintaining accuracy.
Why it matters
Potential benefit: If successful, this study could streamline the diagnostic process for primary aldosteronism, making it less burdensome for patients.
How similar studies have gone: While this approach is exploratory, similar studies have shown promise in simplifying diagnostic methods for endocrine disorders.
Who can join: the full rules
Show full inclusion / exclusion criteria
PA patients: Inclusion criteria: * Patients with hypertension and hypokalemia who have been diagnosed with primary aldosteronism following the latest version international guidelines for primary aldosteronism. * Age: 20-70 years old, male and female; * BMI: 18.5-23.9 kg/m2; Exclusion criteria: * Other causes of endocrine hypertension including pheochromocytoma, Cushing syndrome, etc. * Renal artery stenosis and low potassium due to other factors, such as renal tubular acidosis, Bartter syndrome, Gitelman syndrome, etc. * History of hyperthyroidism, hepatic and renal insufficiency, malignant tumors, metabolic diseases, cardiovascular diseases, and mental diseases,menstrual disorders Healthy volunteers Inclusion criteria: * Age: 20-70 years old, male and female; * BMI: 18.5-23.9 kg/m2; * Blood pressure: 90-120/60-80 mmHg on three consecutive office blood pressure readings; * Female must have regular menstrual cycle (blood and urine samples should be taken during the non-menstrual period); * Regular dietary habits; * No medications taken within the past 1 month. Exclusion criteria: * History of hypokalemia. * History of liver and kidney dysfunction, malignant tumors, metabolic disorders, cardiovascular diseases, and psychiatric disorders, etc. * Menstrual irregularities and taking contraceptive pills. * History of hypertension * Have taken any drugs including anti-inflammatory drugs, potassium diuretics, or special health products in the 4 weeks prior to the examination,
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Tong Anli
- Email: tonganli@hotmail.com
- Phone: +8613460884085
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Kidney stiffness measured by ultrasound in hypertension and healthy volunteers
This study tests whether kidney stiffness measured by a non-invasive ultrasound method differs between people with high blood pressure and healthy individuals.
-
Inclisiran vs. Statin for Primary Aldosteronism
This trial tests whether inclisiran plus amlodipine works differently from a statin-based approach in people with primary aldosteronism and high blood pressure.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Metomidate PET-CT vs Usual Care for Primary Aldosteronism
This study tests whether [11C] metomidate PET-CT can help orient treatment for people with primary aldosteronism compared with the usual adrenal venous sampling approach.
-
Captopril Test with LC-MS/MS for Aldosterone and Renin in Primary Aldosteronism
This study tests whether measuring aldosterone with LC-MS/MS during a captopril test can better diagnose primary aldosteronism.
-
Finerenone vs. Spironolactone for Primary Aldosteronism
This trial tests whether finerenone works as well as spironolactone to lower blood pressure and improve related health measures in adults with primary aldosteronism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.